C/ BASE NO CPA 2026_6 - CABOZANTINIB 20 MG COMP + TEPOTINIB 225 MG COMP
TED · 738789-2026Award noticeawardedNo deadline given
Value
Estimated€240,680 · 240,679.96 EUR
Awarded—
WinnerIPSEN PORTUGAL - PRODUTOS FARMACÊUTICOS, S.A. | MERCK, S.A.
Who already wins at this buyer
Firms with recorded awards from Unidade Local de Saúde de Coimbra, EPE in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| Brainlab Sales GmbH | 2 | €2,619,329 | 2026-10-08 |
| Cencora 3Pl Portugal, S.A. | 2 | €823,396 | 2026-10-27 |
| Roche Farmacêutica Química, Lda. | 2 | — | 2026-10-08 |
| Takeda Farmacêuticos Portugal, Lda | 1 | €1,828,250 | 2026-07-17 |
| Cencora 3PL Portugal, S.A. | 1 | €1,435,097 | 2026-07-20 |
Full buyer profile: what Unidade Local de Saúde de Coimbra, EPE buys and who wins it →
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Aquisição de "CABOZANTINIB 20 MG COMP" e "TEPOTINIB 225 MG COMP" C/ BASE NO CPA 2026_6
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-10-08 | C/ BASE NO CPA 2025_1589 - AMIVANTAMAB 1600 MG/10 ML+AMIVANTAMAB 2240 MG | Unidade Local de Saúde de Coimbra, EPE PT | 94% |
| 2026-10-08 | C/ BASE NO CPA 2025_1303 - OCRELIZUMAB 920 MG/23 ML SOL INJ FR 23 ML SC | Unidade Local de Saúde de Coimbra, EPE PT | 94% |
| 2026-08-17 | C/ BASE NO CPA 2024_900 - LAMIVUDINA 300 MG + DOLUTEGRAVIR 50 MG COMP | Unidade Local de Saúde de Coimbra, EPE PT | 94% |
| 2026-10-20 | 2026/0006 - TRAMETINIB [2 MG CÁP/ COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 94% |
| 2026-05-12 | 261G000513 - C.Central Medicamentos 2026 - 2026/0234 - UPADACITINIB | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-10-20 | 2026/0006 - OLAPARIB [150 MG CÁP/ COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |